CK-0045
Obesity and Type 2 Diabetes
Key Facts
About Cytoki Pharma
Cytoki Pharma is a Danish biotech founded in 2019, focused on harnessing the therapeutic potential of the cytokine IL-22. The company's core technology involves engineering lipidated, long-acting IL-22 analogues, with its lead program, CK-0045, in-licensed from Novo Nordisk and now in Phase 2 development for obesity and type 2 diabetes. Cytoki is backed by prominent European life science investors and is led by a team with deep expertise in IL-22 biology and drug development. The company aims to establish IL-22 as a novel treatment paradigm that drives disease modification beyond weight loss alone.
View full company profileAbout Cytoki Pharma
Cytoki Pharma is a Danish biotech founded in 2019, focused on harnessing the therapeutic potential of the cytokine IL-22. The company's core technology involves engineering lipidated, long-acting IL-22 analogues, with its lead program, CK-0045, in-licensed from Novo Nordisk and now in Phase 2 development for obesity and type 2 diabetes. Cytoki is backed by prominent European life science investors and is led by a team with deep expertise in IL-22 biology and drug development. The company aims to establish IL-22 as a novel treatment paradigm that drives disease modification beyond weight loss alone.
View full company profileTherapeutic Areas
Other Obesity and Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| APN-sEVs | Ciloa Bio | Pre-clinical |
| Prometheus-based Gene Therapy | Remedium Bio | Pre-clinical |